These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 18000213)

  • 1. Estrogen receptors in BRCA1-mutant breast cancer: now you see them, now you don't.
    Jordan VC
    J Natl Cancer Inst; 2007 Nov; 99(22):1655-7. PubMed ID: 18000213
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
    Hosey AM; Gorski JJ; Murray MM; Quinn JE; Chung WY; Stewart GE; James CR; Farragher SM; Mulligan JM; Scott AN; Dervan PA; Johnston PG; Couch FJ; Daly PA; Kay E; McCann A; Mullan PB; Harkin DP
    J Natl Cancer Inst; 2007 Nov; 99(22):1683-94. PubMed ID: 18000219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: Tamoxifen may be an effective treatment for BRCA1-related breast cancer irrespective of estrogen receptor status.
    Cappelletti V; Veneroni S; Coradini D; Oriana S; Tomasic G; Younes M; Daidone MG
    J Natl Cancer Inst; 2003 Apr; 95(8):629-30. PubMed ID: 12697859
    [No Abstract]   [Full Text] [Related]  

  • 4. How is tamoxifen's action subverted?
    Jordan VC
    J Natl Cancer Inst; 2000 Jan; 92(2):92-4. PubMed ID: 10639501
    [No Abstract]   [Full Text] [Related]  

  • 5. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
    Reijm EA; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; van Gelder ME; Sieuwerts AM; Sleijfer S; Foekens JA; Berns EM
    Breast Cancer Res Treat; 2011 Jan; 125(2):387-94. PubMed ID: 20306127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: a brief overview.
    Terakawa N
    Oncology; 2000; 59 Suppl 1():3-4. PubMed ID: 11096349
    [No Abstract]   [Full Text] [Related]  

  • 7. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
    Lusa L; Peissel B; Manoukian S; Marchesi E; Radice P; Pierotti MA; Gariboldi M
    J Natl Cancer Inst; 2008 May; 100(10):752-3; author reply 753-4. PubMed ID: 18477803
    [No Abstract]   [Full Text] [Related]  

  • 9. [Response to tamoxifen in estrogen receptor-positive cell line MCF-7 is independent of p53 expression].
    Shtam TA; Pantina RA; Varfolomeeva EIu; Filatov MV
    Vopr Onkol; 2007; 53(2):194-9. PubMed ID: 17663174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of estrogen receptor alpha, retinoic acid receptor alpha and cellular retinoic acid binding protein II genes is coordinately regulated in human breast cancer cells.
    Lu M; Mira-y-Lopez R; Nakajo S; Nakaya K; Jing Y
    Oncogene; 2005 Jun; 24(27):4362-9. PubMed ID: 15870697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pak up your breast tumor--and grow!
    Jordan VC
    J Natl Cancer Inst; 2006 May; 98(10):657-9. PubMed ID: 16705113
    [No Abstract]   [Full Text] [Related]  

  • 12. BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription.
    Harte MT; O'Brien GJ; Ryan NM; Gorski JJ; Savage KI; Crawford NT; Mullan PB; Harkin DP
    Cancer Res; 2010 Mar; 70(6):2538-47. PubMed ID: 20215511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.
    Revillion F; Pawlowski V; Lhotellier V; Louchez MM; Peyrat JP
    Anticancer Res; 2003; 23(2B):1455-60. PubMed ID: 12820409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine therapy for the treatment of postmenopausal women with breast cancer.
    Harichand-Herdt S; Zelnak A; O'Regan R
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):187-98. PubMed ID: 19192957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.
    Hiscox S; Jordan NJ; Jiang W; Harper M; McClelland R; Smith C; Nicholson RI
    Endocr Relat Cancer; 2006 Dec; 13(4):1085-99. PubMed ID: 17158755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AND-34/BCAR3 differs from other NSP homologs in induction of anti-estrogen resistance, cyclin D1 promoter activation and altered breast cancer cell morphology.
    Near RI; Zhang Y; Makkinje A; Vanden Borre P; Lerner A
    J Cell Physiol; 2007 Sep; 212(3):655-65. PubMed ID: 17427198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fulvestrant, a selective estrogen receptor down-regulator, sensitizes estrogen receptor negative breast tumors to chemotherapy.
    Jiang D; Huang Y; Han N; Xu M; Xu L; Zhou L; Wang S; Fan W
    Cancer Lett; 2014 May; 346(2):292-9. PubMed ID: 24462822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gonadotropins stimulate growth of MCF-7 human breast cancer cells by promoting intracellular conversion of adrenal androgens to estrogens.
    Tanaka Y; Kuwabara K; Okazaki T; Fujita T; Oizumi I; Kaiho S; Ogata E
    Oncology; 2000; 59 Suppl 1():19-23. PubMed ID: 11096352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
    Kim K; Thu N; Saville B; Safe S
    Mol Endocrinol; 2003 May; 17(5):804-17. PubMed ID: 12576490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.